A single amino acid substitution, Phe98 to Tyr98, in dihydrofolate reductase (DHFR) is the molecular origin of trimethoprim (TMP) resistance in Staphylococcus aureus. This active site amino acid substitution was found in all S. aureus TMP-resistant clinical isolates tested. In order to explore the structural role of Tyr98 in TMP-resistance the ternary complexes of the chromosomal S. aureus DHFR (SaDHFR) with methotrexate (MTX) and TMP in the presence of nicotinamide adenine dinucleotide phosphate (NADPH) as well as that of mutant Phe98Tyr DHFR SaDHFR(F98Y) ternary folate-NADPH complex have been determined by X-ray crystallography. Critical evidence concerning the resistance mechanism has also been provided by NMR spectral analyses of 15 
The problem of bacterial resistance to many of todays antimicrobial agents is well known (Cohen, 1992 (Cohen, , 1994 Davies, 1994; Neu, 1992; Spratt, 1994) .
One of the most worrying trends is the increasing incidence of multi-resistant Staphylococcus aureus (MRSA) in hospitals, a frequent cause of life-threatening infections. There is a single reliable agent (vancomycin) against multi-resistant S. aureaus, which is in itself a very precarious situation. If the vancomycin resistance that is already observed in enterococci spreads to staphylococci, it could cause serious clinical problems. The dihydrofolate reductase inhibitor trimethoprim (TMP), often used in combination with sulfamethoxazole (SMZ), was introduced primarily for the treatment of community-acquired infections, particularly of the urinary and respiratory tract, with emphasis on Gram-negative pathogens. However, it is active against bacteria resistant to many other classes of antibiotic and has found use in the treatment of staphylococcal infections.
Resistance to TMP (Figure 1) was very rare before 1983, and only 1% to 6% of clinical isolates were reported to be TMP-resistant (Brum®tt et al., 1983; Lewis & Lacey, 1973 (Archer et al., 1986; Lyon et al., 1983 (Houvinen et al., 1995; Genetic studies have identi®ed two plasmid encoded TMP-resistant DHFRs in staphylococci, the S1 DHFR and S2 DHFR encoded by the genes dfrA and dfrD respectively (Rouch et al., 1989; Dale et al., 1995b) . Whereas the S2 DHFR was only found in a single TMP-resistant S. haemolyticus isolate, the S1 DHFR has been found in S. aureus, S. epidermidis, S. haemolyticus, S. hominis, and S. capitis, suggesting that staphylococci share a common gene pool (Archer et al., 1986 (Archer et al., , 1994 Galetto et al., 1987; Leelaporn et al., 1994 (Dale et al., 1993 (Stu È ber et al., 1990) . Single colonies of E. coli M15(pRep4) harbouring expression plasmids were grown over-night in Luria-Bertani medium with ampicillin (100 mg/ml) and kanamycin (25 mg/ml) and innoculated into 1 l of the same medium. The cells were grown at 37 C to an A 600 of 0.7 and gene expression was induced with IPTG (2 mM). The recombinant proteins were puri®ed as described previously (Dale et al., 1994a,b 
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Trimethoprim Resistance in S. aureus DHFR ance (Dale et al., 1995a) . Recently, we have used a polymerase chain reaction (PCR) approach to study the molecular epidemiology of the gene encoding the S1 DHFR among TMP-resistant staphylococcal clinical isolates (Dale et al., 1995b (Archer et al., 1986; Coughter et al., 1987; Dale et al., 1995b; Lyon et al., 1983 (Dale et al., 1994a (Dale et al., 1993 (Dale et al., 1994b (Dale et al., 1995a (Hodel et al., 1992) (Gerber, 1992) . SaDHFR and SaDHFR(F98Y) were puri®ed as described (Dale et al., 1994a (Kabsch, 1988) and data reduction with the CCP4 suite (CCP4, 1994) . The data collection statistics for the MTX, folate and TMP complexes were as follows: number of measurements, 42,126/25,575/16,629; number of independent re¯ections, 8,653/6,980/4,932; completeness (%), 93.4 (Fitzgerald, 1988) using the re®ned coordinates of the homologous E. coli enzyme as determined in the ternary complex with methotrexate and NADP (Bystroff et al., 1990 (Leelaporn et al., 1994; Nikaido, 1994 (Table 3) . TMP has a pK value above 7 (Roth & Sterlitz, 1969) (Bevan et al., 1985; Birdsall et al., 1989; Feeney, 1995) . TMP is protonated in both ternary complexes, consistent with the H-bonding to the Asp27 observed in the wild-type complex by Xray crystallography (Figure 2) . Unambiguous proof that the protonation in the mutant complex also occurs on N-1 comes from 15 N-edited NOESY spectra (Wider et al., 1991; Sklenar et al., 1993) Figure 1 ). This rules out the folate like binding mode reported for other systems (Birdsall et al., 1989; Cheung et al., 1993) , with the inhibitor¯ipped by 180 around its C2 to C5 axis, thereby moving N-3 to within H-bonding distance to Asp27. Figure 1) (Bru È nger, 1992) using the force ®eld parameters described by Engh & Huber (1991) and a modi®ed parameter set for bulk solvent correction (D. Kostrewa, personal communication re¯ections used, 7262/ 6946/ 4755; total number of non-hydrogen atoms, 1388/1382/1370; ®nal R-factor, 17.7%/15.1%/16.6 %; root-mean-square (r.m.s.) deviations from target values for bonds, 0.011/0.010/ 0.011 and for angles, 2.07/ 2.01/1.95; 42.2/ 37.3/ 31.8; 41.7/38.3/ 28.9; 92, 98 in A Ê 2 ; 27.9, 27.4, 30.8/26.5, 29.7, 22.1/18.9, 23.0, 19.2; number of solvent atoms included, 33/27/ 27 (Arthur & Courvalin, 1993; Dessen et al., 1995) .
(to 2.4 A Ê )/93.7(to 2.5 A Ê )/91.0(to 2.8 A Ê ); R merge 0.076/0.071/0.091 (R merge AEjI(k)-h I i |/AEI(k), where I(k) and hIi are the intensity values for individual measurements and of the corresponding mean values; the summation is over all measurements). The structure of the ternary complex with MTX was solved by molecular replacement with the MERLOT software

, which show intramolecular NOE cross-peaks from the proton on the ring nitrogen in question to protons H-6 and H 2 N-2 and not to H 2 N-4 (
Proton and nitrogen chemical shifts of HN-1 and H 2 N-2 (Table 3) and their proton-proton NOE patterns observed for both complexes are identical. Chemical shifts and NOE cross-peaks that differ between the two enzymes involve just the two protons implicated in the structural changes, those on the 4-amino group of the inhibitor. The proton H a is identi®ed as that cis to N-3 (
These data from sequencing, kinetic, crystallographic and NMR spectroscopic studies suggest a common molecular mechanism for trimethoprim resistance in S. aureus, involving the mutation of the phenylalanine residue 98 of the DHFR to a tyrosine residue. The net loss in binding energy through the disruption of a H-bond at the 4-amino group of TMP has been estimated to be about 9.6 kJ/mol by comparing the E. coli and chicken DHFR-TMP complexes (Roberts et al., 1986) (Iwakura et al., 1988 (Iwakura et al., , 1982 (Blakley, 1984; Chen et al., 1987) . Mutagenesis studies have indicated that the Tyr98-dependent mechanism of TMP-resistance in S. aureus can partially be offset by alternating Phe92 and Val31 in the active site (Dale et al., unpublished results (Sùrensen & Ernst, 1983), ( 1 N, 15 N) one-bond and multiple-bond correlation spectra via multiple coherence (Bax et al., 1983; Bax & Summers, 1986) and 15 N-edited NOESY spectra (Wider et al., 1991; Sklenar et al., 1993) N-1, N-2, N-3 and N-4 (Figure 1) 
